Prevalence of Hepatitis B, C, and D among Thalassemia patients in Sulaimani Governorate

Abstract = 27 times | PDF = 74 times

Main Article Content

Salih Ahmed Hama Moaid Ibrahim Sawa


Infectious diseases are the leading cause of mortality worldwide, with hepatitis viruses in particular making global impact on socioeconomic development and this infection remains a serious public health issue. This study was performed to investigate the prevalence of Hepatitis B, C and D among multi-transfused risk groups in Sulaimani Governorate, 120 major thalassemic patients were tested by serological and enzyme-linked immunosorbent assay (ELISA) technique and Recombinant ImmunoBlot Assay (RIBA) test was done as a confirmatory test for all HCV ELISA positive patients. It was observed that the prevalence of HCV was higher (29.1%) comparing to HBV (22.5%) and HDV (3.3%). The prevalence of HCV-HBV coinfection was (5%), HCV-HBV-HDV coinfections were (0.83%). Statistical analysis showed that the age was significantly effective on the prevalence of HBV (p = 0.009), parenteral medication users showed a significant relation with HBV and HCV prevalence (p = 0.03 and 0.041) respectively. The blood transfusion frequency was significantly related to HBV and HCV prevalence (p = 0.042 and 0.035) respectively. It was noticed that vaccination significantly related to HBV prevalence among thalassemic patients (p = 0.002).


Download data is not yet available.

Article Details


1. Y. A. Johnsosn, J. Graeme, M. Alexander, A. Alfredo, “Viral hepatitis. Gut Supplement; pp. S47- S62, 1991.
2. A. J. Zuckerman. Alphabet of hepatitis viruses. Lancet; 347:558-9. 1996.
3. C. Seeger; W. S. Mason. Hepatitis B virus biology. Microbiol Mol Biol Rev; 64:51-68. 2000.
4. D. Ganem; A. M. Prince. Hepatitis B infection: natural history and clinical consequences. N Engl J Med; 350:1118-29. 2004.
5. J. E. Maynard; M. A. Kane; M. J. Alter; S. C. Hadler. Control of hepatitis B by immunization: global perspective. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R Liss Inc., pp. 967-9. 1988.
6. F. B. Hollinger; T. J. Liang. Hepatitis B virus. In: Knipe D. M; Howley P. M; and editors. Fields Virology. 4th edition. Philadelphia: Lippincott Williams and Wilkins; pp. 2971 -3036. 2001.
7. L. F. He; D. Alling; T. Popkin; M. Shapiro; H. J. Alter; R. H. Purcell. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis; 156, 636-640. 1987.
8. K. Ohba; M. Mizokami; J. Y. Lau; E. Orito; K. Ikeo; T. Gojobori. Evolutionary relationship of hepatitis C, pesti-, flavi-, plantviruses, and newly discovered GB hepatitis agents. FEBS Lett; 378, 232-234. 1996.
9. Y. K. Shimizu; S. M. Feinstone; M. Kohara; R. H. Purcell; H. Yoshikura. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology; 23 (2):205-9. 1996.
10. WHO. Weekly epidemiological record: World Health Organization. 1999.
11. S. H. Mehta; A. Cox; D. R. Hoover. Protection against persistence of hepatitis C. Lancet; 359: 1478-83. 2002.
12. G. Luo; S. Xin; Z. Cai. Role of the 5'-proximal stem-loop structure of the 5' untranslated region in replication and translation of hepatitis C virus RNA. J Virol; 77, 3312-3318. 2003.
13. J. Fernandez; D. Taylor; D. R. Morhardt; K. Mihalik; M. Puig; C. M. Rice; S. M. Feinstone; M. E. Major. Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol; 78, 9782-9789. 2004.
14. J. P. Monjardino; J. A. Saldanha. Delta hepatitis. The disease and the virus. Br Med Bull; 46(2): 399–407. 1990.
15. M. M. C. Lai, “Hepatitis Delta virus. In: Encyclopedia of Virology (Webster RG, Granoff A, editors), London: Academic Press Ltd, pp. 574–580, 1994.
16. M. Rizzetto, B. Hoyer, M. G. Canese, J. W. K. Shih, R. H. Purcell, J. L. Gerin, “Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees, Proc Natl Acad Sci USA, vol. 77, pp. 6124–6128, 1980.
17. T. I. Huo; J. C. Wu; S. I. Wu; A. L. Chang; S. K. Lin; C. H. Pan; Y. H. Huang; F. Y. Chang; S. D. Lee. Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. J Med Virology; 72: 41–45. 2003.
18. M. C. C. Lai. The molecular biology of hepatitis Delta virus. Annual Review of Biochemistry; 64:259-286. 1995.
19. J. M. Taylor. Hepatitis Delta virus and its replication. In: Fields Virology (Fields B.N, Knipe D.M, Howley P.M, editors), 3rd edn. Philadelphia: Lippincott-Raven; pp. 2809–2818. 1996.
20. R. H. Purcell; J. L. Gerin. Hepatitis Delta virus. In: Knipe D. M; Howley P. M; and editors. Fields Virology. 3th edition. Philadelphia: Lippincott Williams and Wilkins; pp. 2819–2829. 1996.
21. T. N. Williams; B. Wonke; S. M. Donohue. A study of hepatitis B and C prevalence and liver function in multiply transfused thalassemic and their parents. Indian Pediatrics; 29(9):1119-24. 1992.
22. M. Montalembert; R. Cirot. Infections In Thalasscmie Patients (Hepatitis And Bone Marrow Trans¬plantation Related Infections Excluded). Prog. Clin. Biol. Res; 309:231-238. 1989.
23. G. B. Schreiber; M. P. Busch; S. H. Kleinman; J. J. Korelitz. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med; 334(26):1685-90. 1996.
24. S. Khalil; H. S. Khan; P. Akhtar. Status of Hepatitis B and C in Beta Thalassemia Major Patients. Journal of Islamabad Medical & Dental College (JIMDC); 5 (2): 71-73. 2016.
25. E. Angelucci; F. Pilo. Treatment of hepatitis C in patients with thalassemia. Haematologica; 93 (8): 1121-1123. 2008.
26. M. M. Ansar; A. Kooloobandi. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat; 9(5):390-2. 2002.
27. G. Sirchia.; A. Bellobuono; A. Giovanetti and M. Marconi. Antibodies To Hepatitis C Virus In Italian Blood Donors. Lancet; 11:797. 1989.
28. P. Triadou; A. Regnat-Lusinciii; R. Cirot. Use of Ferritin/Alanine Aspartate Transaminase Ratio As An Iron Overload Marker Independent Of Liver Cell Damage. Europ.J. I [Acmatol.], 43:423-427. 1989.
29. M. A. F. El-Hazmi; and S. Ramia. Frequencies of Hepatitis B, Delta and Human Immune Deficiency Virus Markers in Multitransfused Saudi Patients with Thalas¬semia and Sickle-Cell Disease. J. Trop. Med. Hyg; 92:1-5. 1989.
30. C. Politis. Complications of blood transfusion in thalassemia. Prog. Clin. Biol. Res.; 309:67-76. 1989.
31. D. T. Covas; E. B. Neto; M. A. Zago. The frequency of blood-borne viral infections in a population of multitransfused Brazilian patients. Rev. Inst. Med. Trop. Sao Paulo; 35 (3): 271-273. 1993.
32. D. Prati; A. Zanella; E. Farma. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood; 92:3460-3464. 1998.
33. K. Q. Hu. Occult hepatitis B virus infection and its clinical implications. J. Viral Hepatitis; 9: 243-257. 2002.
34. S. Miemomen; S. M. Alavian; B. Hajarizadeh; J. Kafaee; B. Yektaparast. Epidemiology of hepatitis B, hepatitis C and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: A multicenter study. Arch. Iran Med.; 9: 319-323. 2006.
35. J. P. Allain. Occult hepatitis B virus infection: Implications in transfusion. Vox Sang, 86: 83-91. 2004.
36. J. A. Marero; A. S. Lok. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology; 126: 347-350. 2004.
37. H. Toyoda; K. Hayashi; Y. Murakami; T. Honda; Y. Katano. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J. Med. Virology; 73: 195-199. 2004.
38. A. Tamaddoni; I. Mohammadzadeh; O. Ziaei. Seroprevalence of HCV Antibody among Patients with β-Thalassemia Major in Amirkola Thalassemia Center, Iran. Iran J Allergy Asthma Immunol March; 6(1): 41-43. 2007.
39. M. Costello; I. M. Sabatini; M. Yungbluth. Viral infections. In: “Clinical Diagnosis and Management by Laboratory Methods. (McPherson RA, Pincus MR, eds)”. Henry's 22nd ed. Philadelphia, PA: Elsevier Saunders, 2011.
40. M. D. Khaled. Prevalence of hepatitis B, hepatitis C and human immunodeficiency virus infections among thalassemia patients in Nineveh governorate, Iraq. Egypt. J. Exp. Biol. (Zool.), 10(1): 85–87. 2014.
41. U. Saeed; Y. Waheed; M. Ashraf; U. Waheed; S. Anjum and M. Sohail. Estimation of hepatitis B Virus, hepatitis c Virus, and different clinical Parameters in the Thalassemic Population of capital Twin cities
of Pakistan. Virology: Research and Treatment; 6: 11–16. 2015.
42. S. Khalil; H. S. Khan; P. Akhtar. Status of Hepatitis B and C in Beta Thalassemia Major Patients. Journal of Islamabad Medical & Dental College (JIMDC); 5 (2): 71-73. 2016.
43. S. A. Hama. Hepatitis C seropositivity and RNA detection among Type2 Diabetic patients in Sulaimani Governorate- Iraqi Kurdistan Region. Journal of Zankoy Sulaimani-A-.18-4; 1-8. 2016